A detailed history of Sandy Spring Bank transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Sandy Spring Bank holds 135 shares of VKTX stock, worth $8,892. This represents 0.0% of its overall portfolio holdings.

Number of Shares
135
Previous 135 -0.0%
Holding current value
$8,892
Previous $7,000 14.29%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

SELL
$17.4 - $94.5 $261 - $1,417
-15 Reduced 10.0%
135 $11,000
Q1 2023

May 05, 2023

SELL
$8.08 - $17.33 $808 - $1,732
-100 Reduced 40.0%
150 $2,000
Q1 2021

May 03, 2021

SELL
$5.74 - $9.67 $516 - $870
-90 Reduced 26.47%
250 $2,000
Q4 2020

Feb 03, 2021

BUY
$5.3 - $6.71 $1,802 - $2,281
340 New
340 $2,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Sandy Spring Bank Portfolio

Follow Sandy Spring Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.